Clinical Trial Update: Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of sacituzumab govitecan and tagitanlimab in previously treated locally advanced or metastatic triple-negati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• TRODELVY (sacituzumab govitecan)
• Tagitanlimab

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Triple Negative Breast Cancer (TNBC), PD-L1 Positive | Phase 2 | Status: NOT_YET_RECRUITING